SCHEMBL2498339

SCHEMBL2498339

CCN(N1CCCC1)S(=O)(=O)c1ccc(Nc2ncc(NC(=O)c3cc(NC(=O)c4cccc(C(F)(F)F)c4)ccc3Cl)cn2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 15/20 0.61
▸ LCK P06239 11/20 0.56
▸ CSF1R P07333 4/20 0.55
▸ MAPK14 Q16539 2/20 0.55
▸ ABL1 P00519 1/20 0.55
▸ FYN P06241 1/20 0.55
▸ LYN P07948 1/20 0.55
▸ SRC P12931 1/20 0.55
▸ KDR P35968 1/20 0.55
▸ MAPK9 P45984 1/20 0.55
▸ TEK Q02763 1/20 0.55
▸ BLK P51451 3/20 0.54
▸ JAK2 O60674 1/20 0.53
▸ PDGFRB P09619 1/20 0.53
▸ FGFR1 P11362 1/20 0.53
▸ CYP2C9 P11712 1/20 0.53
▸ BRAF P15056 1/20 0.53
▸ EPHB4 P54760 1/20 0.53
▸ PTK2 Q05397 1/20 0.53
▸ EGFR P00533 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2495247 0.94 BTK (0.63) BTKLCKCSF1RMAPK14ABL1
SCHEMBL2499026 0.87 BTK (0.62) BTKLCKCSF1RMAPK14ABL1
SCHEMBL5996242 0.84 ALDH1A1 (0.48) LCKMAPK14ABL1SRCKDR
SCHEMBL2498334 0.82 BTK (0.61) BTKLCKCSF1RMAPK14ABL1
SCHEMBL2495540 0.82 BTK (0.61) BTKLCKCSF1RMAPK14ABL1
SCHEMBL5997326 0.82 KMT2A (0.46) LCKMAPK14ABL1KDR
SCHEMBL14303238 0.81 BTK (0.66) BTKLCKCSF1RMAPK14BLK
SCHEMBL5998288 0.81 LCK (0.56) LCKMAPK14JAK2CYP2C9
SCHEMBL2497726 0.81 BTK (0.83) BTKLCKCSF1RMAPK14BLK
SCHEMBL2493840 0.80 BTK (0.79) BTKLCKCSF1RMAPK14BLK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8030487-B2 2-amino—5-substituted pyrimidine inhibitors TARGEGEN, INC. (US) 2011-10-04 — — US disclosed
US-20080027070-A1 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS TARGEGEN, INC. (US) 2008-01-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027070-A1 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS KDR, FLT4, FLT1 BTK 44/4885LCK 9/4885CSF1R 575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback